Natera, Inc. (NASDAQ:NTRA) CEO Sells $2,245,925.00 in Stock

Natera, Inc. (NASDAQ:NTRA – Get Rating) CEO Steven Leonard Chapman sold 40,835 shares of the business’s stock in a transaction dated Thursday, March 2nd. The stock was sold at an average price of $55.00, for a total transaction of $2,245,925.00. Following the sale, the chief executive officer now directly owns 205,128 shares in the company, valued at approximately $11,282,040. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, February 28th, Steven Leonard Chapman sold 13,474 shares of Natera stock. The stock was sold at an average price of $48.94, for a total value of $659,417.56.
• On Monday, January 23rd, Steven Leonard Chapman sold 5,370 shares of Natera stock. The shares were sold at an average price of $41.56, for a total value of $223,177.20.
• On Tuesday, January 3rd, Steven Leonard Chapman sold 8,212 shares of Natera stock. The stock was sold at an average price of $39.55, for a total value of $324,784.60.
• On Wednesday, December 28th, Steven Leonard Chapman sold 2,605 shares of Natera stock. The shares were sold at an average price of $39.84, for a total value of $103,783.20.
• On Friday, December 23rd, Steven Leonard Chapman sold 1,660 shares of Natera stock. The stock was sold at an average price of $42.30, for a total transaction of $70,218.00.
• On Wednesday, December 7th, Steven Leonard Chapman sold 2,645 shares of Natera stock. The stock was sold at an average price of $38.31, for a total transaction of $101,329.95.

Natera Stock Up 2.9 %

Shares of NTRA opened at $58.12 on Friday. The firm has a market cap of $6.58 billion, a PE ratio of -10.43 and a beta of 1.20. The company has a quick ratio of 2.95, a current ratio of 3.90 and a debt-to-equity ratio of 0.40. The company’s fifty day moving average is $43.71 and its two-hundred day moving average is $43.89. Natera, Inc. has a fifty-two week low of $26.10 and a fifty-two week high of $60.67.

Natera (NASDAQ:NTRA – Get Rating) last announced its quarterly earnings results on Tuesday, February 28th. The medical research company reported ($1.37) EPS for the quarter, topping the consensus estimate of ($1.40) by $0.03. The company had revenue of $217.30 million during the quarter, compared to analyst estimates of $215.50 million. Natera had a negative return on equity of 106.67% and a negative net margin of 66.79%. During the same period in the prior year, the firm posted ($1.48) earnings per share. The firm’s revenue was up 25.6% on a year-over-year basis. Analysts forecast that Natera, Inc. will post -4.45 earnings per share for the current year.

Institutional Investors Weigh In On Natera

Several large investors have recently made changes to their positions in NTRA. Russell Investments Group Ltd. acquired a new stake in Natera in the 3rd quarter valued at $5,083,000. WINTON GROUP Ltd raised its holdings in shares of Natera by 20.5% during the 2nd quarter. WINTON GROUP Ltd now owns 19,595 shares of the medical research company’s stock valued at $694,000 after buying an additional 3,328 shares during the period. Barclays PLC raised its holdings in shares of Natera by 285.1% during the 3rd quarter. Barclays PLC now owns 106,211 shares of the medical research company’s stock valued at $4,655,000 after buying an additional 78,630 shares during the period. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Natera during the 3rd quarter worth approximately $541,000. Finally, Delphia USA Inc. purchased a new position in Natera in the 2nd quarter worth approximately $208,000. Institutional investors and hedge funds own 93.81% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. Morgan Stanley raised their price objective on shares of Natera from $70.00 to $72.00 and gave the stock an “overweight” rating in a research note on Thursday. Piper Sandler boosted their price target on Natera from $70.00 to $80.00 in a report on Friday, February 17th. Credit Suisse Group increased their price objective on Natera from $55.00 to $65.00 and gave the company an “outperform” rating in a research note on Wednesday. BTIG Research cut their target price on shares of Natera from $95.00 to $75.00 in a research note on Wednesday, November 9th. Finally, Raymond James raised their price target on shares of Natera from $58.00 to $68.00 and gave the stock an “outperform” rating in a research note on Friday. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $79.27.

Natera Company Profile

(Get Rating)

Natera, Inc is a diagnostics company, which engages in the discovery, development, and commercialization of genetic testing services. It provides Panorama non-invasive prenatal test (NIPT), Vistara, horizon carrier screening (HCS), spectrum pre-implantation genetic screening and spectrum pre-implantation genetic diagnosis, Anora products of conception (POC) and non-invasive paternity testing (PAT).